Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 8/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050664 | 0.89 | HPGD (0.88) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL30900326 | 0.88 | SIRT6 (0.67) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL1527190 | 0.88 | SIRT6 (0.67) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL30532598 | 0.87 | SIRT6 (0.75) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL6653754 | 0.87 | HPGD (0.97) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL27997682 | 0.87 | SIRT6 (0.75) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL2825311 | 0.87 | HPGD (0.61) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL3837554 | 0.86 | HPGD (1.00) | HPGDMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL573146 | 0.86 | HPGD (1.00) | HPGDMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14419241 | 0.85 | HPGD (0.71) | HPGDSIRT6MAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| EP-3966207-B1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| CN-116669725-A | Novel aminopyridine and use thereof in the treatment of cancer | 奥克兰联合服务有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4217357-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | Auckland Uniservices Limited (NZ) | 2023-08-02 | — | — | EP | disclosed |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1551813-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | disclosed |
| EP-1551813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032882-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142437-A1 | CHEMICAL COMPOUNDS | CDK4, CDK2, CDK3 | HPGD 1445/4885SIRT6 1630/4885MAPT 3337/4885 |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | HPGD 1842/4885SIRT6 521/4885MAPT 940/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | HPGD 740/4885SIRT6 1628/4885MAPT 1370/4885 |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | HPGD 1978/4885SIRT6 651/4885MAPT 817/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | HPGD 1544/4885SIRT6 1778/4885MAPT 142/4885 |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | HPGD 1842/4885SIRT6 521/4885MAPT 940/4885 |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | HPGD 761/4885SIRT6 1471/4885MAPT 4128/4885 |
| US-20050288515-A1 | Chemical compounds | CDK4, CDK2, CDK3 | HPGD 1445/4885SIRT6 1630/4885MAPT 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.